Movement Alert｜WUXI XDC Rises 3.17% in Regular Trading, Driven by Buy Rating and FDA Inspection Milestone

Market Focus

Oct 12

On October 12, WUXI XDC rose 3.17% in regular trading, reaching 84.7 Hong Kong dollars with a turnover of 132 million Hong Kong dollars.

The movement came as Goldman Sachs previously assigned a Buy rating with a target price of 97.9 Hong Kong dollars, citing the upcoming first FDA inspection of its Wuxi production facility as a key catalyst for validating commercial manufacturing capabilities. The company reported mid-year revenue of 3.701 billion yuan, up 37.0% year-over-year, with adjusted net profit of 1.027 billion yuan, up 37.4%, reflecting solid fundamentals. Institutional ratings and commercial milestone expectations combined to drive the stock's strength against a divergent sector backdrop.

WUXI XDC is an investment holding company primarily engaged in providing comprehensive contract research, development and manufacturing organization services for antibody-drug conjugates and other bioconjugates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketb.com/news/1178396670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178396670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178396670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-12 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178396670","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI XDC Rises 3.17% in Regular Trading, Driven by Buy Rating and FDA Inspection Milestone","media":"Market Focus","content":"<p><p>On October 12, WUXI XDC rose 3.17% in regular trading, reaching 84.7 Hong Kong dollars with a turnover of 132 million Hong Kong dollars.</p><p>The movement came as Goldman Sachs previously assigned a Buy rating with a target price of 97.9 Hong Kong dollars, citing the upcoming first FDA inspection of its Wuxi production facility as a key catalyst for validating commercial manufacturing capabilities. The company reported mid-year revenue of 3.701 billion yuan, up 37.0% year-over-year, with adjusted net profit of 1.027 billion yuan, up 37.4%, reflecting solid fundamentals. Institutional ratings and commercial milestone expectations combined to drive the stock's strength against a divergent sector backdrop.</p><p>WUXI XDC is an investment holding company primarily engaged in providing comprehensive contract research, development and manufacturing organization services for antibody-drug conjugates and other bioconjugates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI XDC Rises 3.17% in Regular Trading, Driven by Buy Rating and FDA Inspection Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI XDC Rises 3.17% in Regular Trading, Driven by Buy Rating and FDA Inspection Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-12 10:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 12, WUXI XDC rose 3.17% in regular trading, reaching 84.7 Hong Kong dollars with a turnover of 132 million Hong Kong dollars.</p><p>The movement came as Goldman Sachs previously assigned a Buy rating with a target price of 97.9 Hong Kong dollars, citing the upcoming first FDA inspection of its Wuxi production facility as a key catalyst for validating commercial manufacturing capabilities. The company reported mid-year revenue of 3.701 billion yuan, up 37.0% year-over-year, with adjusted net profit of 1.027 billion yuan, up 37.4%, reflecting solid fundamentals. Institutional ratings and commercial milestone expectations combined to drive the stock's strength against a divergent sector backdrop.</p><p>WUXI XDC is an investment holding company primarily engaged in providing comprehensive contract research, development and manufacturing organization services for antibody-drug conjugates and other bioconjugates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1178396670","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178396670","pubTimestamp":1791773651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 12, WUXI XDC rose 3.17% in regular trading, reaching 84.7 Hong Kong dollars with a turnover of 132 million Hong Kong dollars.The movement came as Goldman Sachs previously assigned a Buy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"走势警报|受买入评级和FDA检查里程碑推动，无锡XDC在常规交易中上涨3.17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On October 12, WUXI XDC rose 3.17% in regular trading, reaching 84.7 Hong Kong dollars with a turnover of 132 million Hong Kong dollars.The movement came as Goldman Sachs previously assigned a Buy rating with a target price of 97.9 Hong Kong dollars, citing the upcoming first FDA inspection of its Wuxi production facility as a key catalyst for validating commercial manufacturing capabilities. The company reported mid-year revenue of 3.701 billion yuan, up 37.0% year-over-year, with adjusted net profit of 1.027 billion yuan, up 37.4%, reflecting solid fundamentals. Institutional ratings and commercial milestone expectations combined to drive the stock's strength against a divergent sector backdrop.WUXI XDC is an investment holding company primarily engaged in providing comprehensive contract research, development and manufacturing organization services for antibody-drug conjugates and other bioconjugates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}